← Eichor
Condition: Iparomlimab And Tuvonralimab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Iparomlimab And Tuvonralimab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Tr
Phase 2 · 1 location(s) · Dai, Guanghai · NCT07392346A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemothera
Phase 2 · 1 location(s) · Shandong Provincial Hospital · NCT06829797SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06864013Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fet
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07289997Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07014150Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07447570Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors
Phase 1/Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06941766Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07389629Iparomlimab and Tuvonralimab in HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT07090317Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT07055399Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Chol
Phase 2 · 1 location(s) · Fudan University · NCT07070700Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
Phase 2 · 1 location(s) · RenJi Hospital · NCT07396324Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as S
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07530445Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Tr
EARLY_Phase 1 · 1 location(s) · JIANG LONGWEI · NCT07343791Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07267078QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07601178Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07150247Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junctio
Phase 2 · 1 location(s) · Daping Hospital and the Research Institute of Surgery of the · NCT07165847Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Can
Phase 2 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT06942416QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07327788Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric
Phase 2 · 1 location(s) · Beijing Friendship Hospital · NCT07315854QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06951997Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07232654SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06936748QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Phase 2 · 1 location(s) · Du Juan · NCT07110064Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
Phase 2 · 1 location(s) · Obstetrics & Gynecology Hospital of Fudan University · NCT06878222The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT06930118A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemoth
NA · 1 location(s) · The Second Affiliated Hospital of Hainan Medical University · NCT07546383
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.